Iovance updates corporate presentation with Q3 2024 financials and pipeline status

IOVANCE BIOTHERAPEUTICS, INC.

Cash and investments of ~$404M as of Sept 30, 2024; Q3 product revenue of $58.6M.
FY 2024 product revenue guidance reaffirmed at $160–$165M.
56 Authorized Treatment Centers (ATCs) as of Nov 7, 2024; over 140 Amtagvi patients treated.
More than 250 million U.S. patient lives covered by payer policies.
Pipeline includes ongoing TILVANCE-301 Phase 3 trial in frontline advanced melanoma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.